Carbon To Carbon Unsaturation Patents (Class 514/560)
-
Publication number: 20140107199Abstract: Orally administrable composition comprising fatty acids comprising omega-3-fatty acids, salts or derivatives thereof are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore.Type: ApplicationFiled: December 17, 2013Publication date: April 17, 2014Applicant: Matinas BioPharma, Inc.Inventors: Abdel Aziz FAWZY, George BOBOTAS, Roelof RONGEN
-
Publication number: 20140107198Abstract: Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore.Type: ApplicationFiled: December 9, 2013Publication date: April 17, 2014Applicant: Matinas BioPharma, Inc.Inventors: George BOBOTAS, Abdel Aziz Fawzy
-
Publication number: 20140107206Abstract: Orally administrable composition comprising fatty acids comprising omega-3-fatty acids, salts or derivatives thereof are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore.Type: ApplicationFiled: December 17, 2013Publication date: April 17, 2014Applicant: Matinas BioPharma, Inc.Inventors: Abdel Aziz FAWZY, George BOBOTAS, Ihor TERLECKYJ
-
Publication number: 20140105999Abstract: This invention relates to an oil composition, preferably obtained from a copepod, and the use thereof to reduce accumulation of visceral fat and counteract impairment of heart function caused by obesity inducing Western diets. The oil composition of the present invention can thus be used to reduce abdominal obesity and improve glucose tolerance and thus to reduce the risk of obesity related diseases such as but not limited to type 2 diabetes or cardiovascular disease, or to prevent or treat such diseases.Type: ApplicationFiled: December 27, 2013Publication date: April 17, 2014Applicant: Calanus ASInventors: Jan Raa, Gunnar Rorstad, Kurt Steinar Tande
-
Publication number: 20140107205Abstract: Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore.Type: ApplicationFiled: December 9, 2013Publication date: April 17, 2014Applicant: Matinas BioPharma, Inc.Inventors: George BOBOTAS, Abdel Aziz FAWZY
-
Publication number: 20140107204Abstract: The present invention provides for a method that includes safely administering via injection ethanolamine and 9-octadecanoic acid, a pharmaceutically acceptable thereof, or a pharmaceutical formulation including the same, to the stomach of a human, e.g., to prevent weight loss reversion, to induce weight loss, and/or control weight loss.Type: ApplicationFiled: August 7, 2013Publication date: April 17, 2014Applicant: QOL Medical LLCInventors: Dayton T. Reardan, Derick Cooper
-
Publication number: 20140107200Abstract: Orally administrable composition comprising fatty acids comprising omega-3-fatty adds, salts or derivatives thereof are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore.Type: ApplicationFiled: December 17, 2013Publication date: April 17, 2014Applicant: MATINAS BIOPHARMA, INC.Inventors: ABDEL AZIZ FAWZY, GEORGE BOBOTAS, IHOR TERLECKYJ
-
Publication number: 20140107063Abstract: Dietary formulations and methods for treating, preventing or delay onset of osteoarthritis in canines and other animals are disclosed. The formulations are enriched in n-3 fatty acids and limited in n-6 fatty acids.Type: ApplicationFiled: December 20, 2013Publication date: April 17, 2014Inventors: Mark K. WALDRON, Steven S. HANNAH
-
Patent number: 8697749Abstract: In view of the situation that a clinically acceptable medical agent which has the action of preventing and relieving the lipotoxicity with no significant side effects is not yet provided, such medical agent is provided. An agent for relieving lipotoxicity which comprises an unsaturated fatty acid containing 18 to 22 carbon atoms and having a degree of unsaturation of 3 to 6 or a derivative thereof as its effective component.Type: GrantFiled: April 28, 2009Date of Patent: April 15, 2014Assignee: Mochida Pharmaceutical Co., Ltd.Inventors: Hitoshi Shimano, Toyonori Kato
-
Patent number: 8697676Abstract: A novel omega-3 fatty acid/lipid based nutraceutical composition and a method of optimizing said omega-3 fatty acid/lipid based nutraceutical composition. The nutraceutical composition and method is based on the insight that different forms of high omega-3 fatty acid lipids (e.g. triglyceride form, ethyl ester form, free fatty acid form, phospholipid form) have different molecular modes and levels of action. Specifically the phospholipid form is likely more effective at promoting membrane fluidity and permeability, while the free fatty acid form is likely more effective at regulating cell receptors, such as the PPAR? receptors, that are responsible for various metabolic effects including lipid metabolism. The desirability of producing omega-3 compositions that may act synergistically and thus more robustly to improve health and to some extent mimic markers of life extension such as shown by caloric restriction, along with specific optimization methods, markers, and compositions are taught.Type: GrantFiled: June 15, 2011Date of Patent: April 15, 2014Inventor: Ronald E Rosedale
-
Patent number: 8697748Abstract: A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.Type: GrantFiled: January 4, 2012Date of Patent: April 15, 2014Assignee: Baylor Research InstituteInventor: Charles R. Roe
-
Publication number: 20140100274Abstract: The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid.Type: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: Matinas BioPharma, Inc.Inventors: George BOBOTAS, Abdel Aziz Fawzy
-
Publication number: 20140100273Abstract: The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid.Type: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: MATINAS BIOPHARMA, INC.Inventors: George BOBOTAS, ABDEL AZIZ FAWZY
-
Publication number: 20140100281Abstract: Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore.Type: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: Matinas BioPharma, Inc.Inventors: George BOBOTAS, Abdel Aziz FAWZY
-
Publication number: 20140100279Abstract: The present invention relates to the discovery that compounds isolated from the leaves of the plant Eucalyptus camaldulensis can be used to treat or prevent hyperglycemia and/or hypertension.Type: ApplicationFiled: October 4, 2013Publication date: April 10, 2014Applicant: THE UNIVERSITY OF THE WEST INDIESInventors: Denise DALEY-BECKFORD, Trevor Herbert YEE, Ruby Lisa ALEXANDER-LINDO, Paul Bancroft REESE
-
Publication number: 20140100280Abstract: Compositions that include Very Long Chain Polyunsaturated Fatty Acids (VLC-PUFAs) are disclosed, along with methods of production and use thereof.Type: ApplicationFiled: November 8, 2013Publication date: April 10, 2014Applicant: THE BOARD REGENTS OF THE UNIVERSITY OF OKLAHOMAInventors: Robert E. Anderson, Martin-Paul Agbaga, Richard S. Brush
-
Publication number: 20140100275Abstract: The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid.Type: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: Matinas BioPharma, Inc.Inventors: George BOBOTAS, Abdel Aziz FAWZY
-
Publication number: 20140100272Abstract: The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid.Type: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: Matinas BioPharma, Inc.Inventors: George BOBOTAS, Abdel Aziz Fawzy
-
Publication number: 20140093554Abstract: The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a large lipid globule size. The composition can be used to increase bone mineral content and/or bone mass density.Type: ApplicationFiled: June 10, 2013Publication date: April 3, 2014Inventors: Eline Marleen VAN DER BEEK, Gelske SPEELMANS, Antonie VAN BAALEN, Annemarie OOSTING, Günther BOEHM
-
Publication number: 20140094519Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.Type: ApplicationFiled: May 12, 2011Publication date: April 3, 2014Inventors: Charles N. Serhan, Reza Dana, Yiping Jin
-
Publication number: 20140094520Abstract: Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore.Type: ApplicationFiled: December 9, 2013Publication date: April 3, 2014Applicant: MATINAS BIOPHARMA, INC.Inventors: George BOBOTAS, Abdel Aziz Fawzy
-
Publication number: 20140093558Abstract: The present invention relates to crystal modifications of racemic (2R,S)- and enantiomerically pure (2R)-resp. (2S)-DOTAP chloride, to processes for the preparation thereof, and to the use thereof for the preparation of pharmaceutical compositions.Type: ApplicationFiled: May 2, 2012Publication date: April 3, 2014Applicant: MERCK PATENT GMBHInventors: Michael Wilhelm Platscher, Alfred Hedinger
-
Patent number: 8686039Abstract: The present invention relates to an aqueous nanoemulsion composition comprising conjugated linoleic acid. More particularly, the present invention relates to an aqueous nanoemulsion composition comprising 5 to 50 wt % of conjugated linoleic acid, 0.01 to 5 wt % of lecithin, 0.01 to 5 wt % of ethanol as a dissolution aid, 1 to 15 wt % of coemulsifier, 10 to 40 wt % of glycerine and the balance of water.Type: GrantFiled: February 19, 2010Date of Patent: April 1, 2014Assignees: Hwail Pharmaceutical Co., Ltd., Yu, Hyo GyoungInventors: Hyo Gyoung Yu, Hong Geun Ji, Hye Kyeong Woo, Soo Dong Kim
-
Patent number: 8686167Abstract: Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.Type: GrantFiled: October 1, 2010Date of Patent: April 1, 2014Assignee: Complexa, Inc.Inventor: Raymond A. Miller
-
Patent number: 8686038Abstract: The present invention relates to methods of treating the side effects of a toxic medical therapy using nitrated lipids. In particular, the methods comprise the use of nitrated fatty acids or esters thereof to treat side effects, including organ system damage, caused by chemotherapy, radiotherapy, and the administration of other toxic agents.Type: GrantFiled: June 18, 2009Date of Patent: April 1, 2014Assignee: The Univsersity of Utah Research FoundationInventor: Tianxin Yang
-
Publication number: 20140088047Abstract: The present invention relates to the use of long chain polyunsaturated fatty acids to treat diseases associated with red blood cells and cell membranes, and in particular to the use of derivatives of long chain fatty acids to treat sickle cell disease.Type: ApplicationFiled: September 24, 2013Publication date: March 27, 2014Applicant: AKER BIOASSIST ASInventors: Nils Hoem, Elizabeth B. Vadas
-
Publication number: 20140088120Abstract: The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.Type: ApplicationFiled: September 26, 2013Publication date: March 27, 2014Applicant: TANGENT REPROFILING LIMITEDInventors: Suzanne Dilly, Gregory Stoloff, Paul Taylor
-
Publication number: 20140088194Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: ApplicationFiled: November 26, 2013Publication date: March 27, 2014Applicant: Amarin Pharmaceuticals Ireland LimitedInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Publication number: 20140079657Abstract: Compositions and methods of treatment are disclosed using compositions of extracts from the fruit of the Synsepalum dulcificum tree, which when applied topically in mammals, can provide benefit for dermatological and joint conditions. The extracts also contain anti-inflammatory, antimicrobial and spermicidal activity in vitro.Type: ApplicationFiled: September 12, 2013Publication date: March 20, 2014Inventors: Elizabeth Resnick, Lionel Resnick, Adam Resnick
-
Publication number: 20140079631Abstract: Described herein are compositions and methods relating to particles comprising at least one component of a cellular-derived microparticle. Aspects of technology described herein relate to compositions and methods for treating inflammation, wounds, and pain.Type: ApplicationFiled: March 23, 2012Publication date: March 20, 2014Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Charles N. Serhan, Lucy V. Norling, Matthew Spite, Jesmond P. Dalli
-
Publication number: 20140080909Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: ApplicationFiled: November 20, 2013Publication date: March 20, 2014Applicant: Amarin Pharmaceuticals Ireland LimitedInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Patent number: 8673976Abstract: A medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis, which comprises a polyprenyl compound (e.g., 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid) as an active ingredient.Type: GrantFiled: June 15, 2012Date of Patent: March 18, 2014Assignee: Kowa Company, Ltd.Inventors: Yuji Yoshikawa, Megumi Yamamoto, Naoto Ishibashi, Mami Seki
-
Patent number: 8673881Abstract: The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.Type: GrantFiled: April 13, 2010Date of Patent: March 18, 2014Assignee: A.T. Resolve SarlInventors: Per Gjorstrup, C. Eric Schwartz
-
Publication number: 20140073692Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.Type: ApplicationFiled: September 16, 2013Publication date: March 13, 2014Applicant: AMARIN PHARMACEUTICALS IRELAND LIMITEDInventors: Malcolm Peet, Krishna S. Vaddadi
-
Patent number: 8668921Abstract: The present invention provides lipase inhibitors containing dimers of flavan-3-ols derived from teas as well as foods and beverages and medicines containing said inhibitors. More specifically, the present invention provides lipase inhibitors containing at least one of assamicains represented by the formula: wherein G represents a galloyl group; theasinensins represented by the formula: wherein R1 represents G or H, and R2 represents G; and theaflavins represented by the formula: wherein R1 and R2 independently represent G or H; as well as foods and beverages and medicines containing said lipase inhibitors.Type: GrantFiled: July 5, 2005Date of Patent: March 11, 2014Assignee: Suntory Holdings LimitedInventors: Masaaki Nakai, Yuko Fukui, Sumio Asami, Fumio Hashimoto
-
Publication number: 20140066508Abstract: A method for ameliorating metabolic syndrome may include administering, to a patient in need thereof, an effective amount of a monounsaturated fatty acid having 22 carbons or a salt or an ester thereof and/or an effective amount of a monounsaturated fatty acid having 20 carbons or a salt or an ester thereof.Type: ApplicationFiled: February 29, 2012Publication date: March 6, 2014Applicant: NIPPON SUISAN KAISHA, LTD.Inventors: Zhi-hong Yang, Hiroko Miyahara, Shuhei Takemura, Akimasa Hatanaka
-
Publication number: 20140066509Abstract: The present disclosure is directed generally to cosmetic compositions comprising EPA free acid and GLA free acid. In some embodiments, the cosmetic compositions have a cosmetically acceptable odor.Type: ApplicationFiled: September 6, 2013Publication date: March 6, 2014Applicant: DIGNITY SCIENCES LIMITEDInventors: Mehar Manku, John Climax, David Coughlan
-
Publication number: 20140066507Abstract: The present disclosure is directed generally to cosmetic compositions comprising EPA free acid and salicylic acid. In some embodiments, the cosmetic compositions have a cosmetically acceptable odor.Type: ApplicationFiled: May 31, 2013Publication date: March 6, 2014Applicant: Dignity Sciences LimitedInventors: Mehar Manku, John Climax, David Coughlan
-
Publication number: 20140066399Abstract: The present invention relates to topical preparations containing N-palmitoyl-vanillamide having hyperalgesic activity. In particular, the invention relates to N-palmitoyl-vanillamide for use in the treatment of pathologies selected from: post-herpetic neuralgia, neuralgia of trigeminus, occipital neuralgia, dental neuralgia, glottopharyngeal neuralgia, uremic neuralgia, diabetic neuralgia, headache of different origin, neuropathic itch, neurogenic itch, uremic itch, vulvodinia, vulvar vestibulitis, ano-rectal pain and itch, balano-preputial pain and itch, painful urogenital disorders of dogs and cats, psoriasis-associated pruritus and pain, itching skin diseases (e.g. atopic dermatitis) in the human and veterinary field, muscular pain, pain of the tendon, osteoarthritis associated pain in humans, dogs and cats; painful eye diseases in the human and veterinary field, inflammatory pathologies of the oral cavity in the human and veterinary field.Type: ApplicationFiled: August 28, 2013Publication date: March 6, 2014Applicant: EPITECH GROUP S.R.L.Inventors: Francesco Della Valle, Luciano De Petrocellis, Sabatino Maione, Vincenzo Di Marzo, Maria Federica Della Valle
-
Patent number: 8664271Abstract: The present invention relates to a novel pharmaceutical formulation comprising an LTB4 agent at an alkaline pH effective to stabilize the LTB4 agent and provide a formulation with an increased shelf-life. The formulation of the present invention has an increased shelf-life of at least 24 months.Type: GrantFiled: September 20, 2005Date of Patent: March 4, 2014Assignee: LTB4 Sweden ABInventor: Pierre Borgeat
-
Patent number: 8663662Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: GrantFiled: November 26, 2012Date of Patent: March 4, 2014Assignee: Amarin Pharma, Inc.Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Publication number: 20140056863Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid eicosapentaenoic acid. It may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, citrulline, ?-ketoglutarate, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.Type: ApplicationFiled: April 18, 2012Publication date: February 27, 2014Applicant: Nestec S.A.Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
-
Publication number: 20140056862Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid and ?-ketoglutarate. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, citrulline, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.Type: ApplicationFiled: April 18, 2012Publication date: February 27, 2014Applicant: Nestec S.A.Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam Kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
-
Publication number: 20140053299Abstract: Disclosed are the complete polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) systems from Schizochytrium, and biologically active fragments and homologues thereof. More particularly, this invention relates to nucleic acids encoding such PUFA PKS systems, to proteins and domains thereof that comprise such PUFA PKS systems, to genetically modified organisms (plants and microorganisms) comprising such PUFA PKS systems, and to methods of making and using the PUFA PKS systems disclosed herein. This invention also relates to genetically modified plants and microorganisms and methods to efficiently produce lipids enriched in various polyunsaturated fatty acids (PUFAs) as well as other bioactive molecules by manipulation of a PUFA polyketide synthase (PKS) system.Type: ApplicationFiled: February 20, 2013Publication date: February 20, 2014Applicant: DSM IP Assets B.V.Inventor: DSM IP Assets B.V.
-
Publication number: 20140050712Abstract: Some aspects of the invention provide for a method of treating hepatic disorders, lipidemias and cardiac-related risk factors using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.Type: ApplicationFiled: April 24, 2012Publication date: February 20, 2014Applicant: RETROTOPE, INC.Inventor: Mikhail S. Shchepinov
-
Patent number: 8652508Abstract: Dietary formulations in the form of an oil emulsion providing total enteral or parenteral nutrition, or in the form of food oil suitable for oral administration is provided. The formulations include about 2-60% by calories of a C20 or longer omega-3 fatty acid and about 0.05% to 1% by calories of arachidonic acid, where the formulation provides less than 1% of total calories from linoleic acid and alpha-linolenic acid, and where the fatty acids provide 5-60% of the total calories of said dietary formulation. Methods for treatment of diseases and disorders using the dietary formulations are also provided.Type: GrantFiled: May 27, 2008Date of Patent: February 18, 2014Assignees: Children's Medical Center Corporation, Beth Israel Deaconess Medical Center, Inc.Inventors: Mark Puder, Bruce Bistrian
-
Publication number: 20140044685Abstract: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality of life especially in the elderly at risk of sarcopenia and frailty. The nutritional compositions include ?-hydroxyisocaproic acid and citrulline. The composition may include other functional ingredients such as, but not limited to whey protein including whey protein micelles, prebiotic fibers, ?-keto-glutarate, eicosapentaenoic acid, L-carnitine, nucleotides, and amino acids. Methods of administering such nutritional products to individuals in need of same are also provided.Type: ApplicationFiled: April 18, 2012Publication date: February 13, 2014Applicant: NESTEC S.A.Inventors: Norman Alan Greenberg, Denis Breuille, Zamzam Kabiry (Fariba) Roughead, Doug Bolster, Jennifer Mager
-
Publication number: 20140045940Abstract: The present invention provides a method of extracting naturally occurring oil bodies comprising obtaining material containing naturally occurring oil bodies, recovering the oil bodies in a wet preparation and drying the oil bodies; and dried oil bodies obtained by the method and uses thereof.Type: ApplicationFiled: February 14, 2012Publication date: February 13, 2014Applicant: THE UNIVERSITY OF NOTTINGHAMInventor: David Gray
-
Publication number: 20140044692Abstract: Some aspects of the invention provide for a method of treating Impaired Energy Processing Disorders and Mitochondrial Deficiencies using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.Type: ApplicationFiled: April 24, 2012Publication date: February 13, 2014Applicant: RETROTOPE, INC.Inventor: Mikhail S. Shchepinov
-
Publication number: 20140045941Abstract: A Salvia hispanica L. derived seed oil extract composition of matter containing from 60-88% PUFAs in a ratio of from 3.1:1-3.3:1 of ALA to LA, 4-10% of C-18 mono-unsaturated fatty acid, 1-5% of C-18 saturated fatty acid and 4-8% of C-16 saturated fatty acid in a mixed triglyceride form stable at room temperature of 12-24 months containing a mixture of selected antioxidants.Type: ApplicationFiled: October 15, 2013Publication date: February 13, 2014Applicant: U.S. NUTRACEUTICALS, LLC d/b/a Valensa InternationalInventors: John A. Minatelli, W. Stephen Hill, Rudi E. Moeck, Uy Nguyen